Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Letno srečanje ASCO
Authors:Čufer, Tanja (Author)
Language:Slovenian
Tipology:1.04 - Professional Article
Organisation:Logo OI - Institute of Oncology
Keywords:klinična onkologija, imunoterapija, imunska zdravila, novosti
Year of publishing:2015
COBISS_ID:2139771 Link is opened in a new window
UDC:616-006
ISSN on article:1408-1741
OceCobissID:65324032 Link is opened in a new window
Views:1972
Downloads:361
Files:.pdf PDF - Presentation file, download (1,18 MB)
 
Journal:Onkologija
Onkološki inštitut
 
Metadata:XML RDF-CHPDL DC-XML DC-RDF
Rights:by Authors
:
  
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:03.01.2018

Secondary language

Language:English
Title:ASCO Annual Meeting
Abstract:In the end of May this year, Chicago hosted the traditional annual meeting of oncologists from around the world, which was organised by the American Society of Clinical Oncology (ASCO). Once again, the meeting was attended by more than 30,000 oncologists and other scientists from all over the world. The main topic of this year’s ASCO meeting was definitely cancer immunotherapy. For many years, we have hoped to be able to destroy or at least control cancer cells by stimulating the organism’s own defence. There have been some ups but mostly many downs of immunotherapy. Interferons, interleukins and vaccines have shown a very small level of efficacy, and, even so, only in some types of cancer, alongside a disproportionally high toxicity. A breakthrough was achieved a few years ago, when new immuno-medicines, inhibitors of control switches in T lymphocytes (so-called checkpoint inhibitors), were introduced into clinical trials. In many types of cancer, these medicines led to remissions, which were, most importantly, long-term in patients with remission.

Archive

niGradiv

Back